Eli Lilly announced plans to build a new manufacturing facility in Houston, Texas, as part of its $27 billion investment in U.S. manufacturing plants. The facility will focus on producing small molecule drugs, including an experimental obesity pill, orforglipron. The company is aiming to address supply constraints and meet the growing demand for these drugs, particularly in the booming market for GLP-1s.
The new Houston site is expected to create 615 jobs in the Greater Houston area and bring 4,000 construction jobs. Eli Lilly’s investment in domestic manufacturing reflects a strategic move to boost production in the U.S. and align with President Donald Trump’s push to re-shore production. The company aims to enhance its ability to manufacture small molecule drugs and fulfill the potential of orforglipron as a treatment for obesity and type 2 diabetes on a global scale.